Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis.
The use of gatifloxacin (GAT) in combination with ethionamide (ETA) with or without pyrazinamide (PZA) for a 12-week treatment period followed by an 8-week observation period was evaluated in a model of tuberculosis in mice. Mice treated with GAT at 300 mg/kg of body weight in combination with ETA (25 mg/kg) for 5 days per week had sterile lungs, whereas mice treated with GAT (100 mg/kg) and ETA (25 mg/kg) had about 10 CFU/lung; however, there was regrowth of the organisms in both groups at the end of the observation period. When PZA (450 mg/kg 5 days per week) was added to the high-dose GAT-ETA regimen, no viable mycobacteria were present after the 8-week observation period. GAT in combination with ETA and PZA has great promise for the treatment of tuberculosis.
Cynamon
Michael H
MH
Department of Medicine, Veterans Affairs Medical Center, Syracuse, New York, USA. Michael.Cynamon@Med.VA.Gov
Sklaney
Mary
M
D000281:Administration, Intranasal; D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000627:therapeutic use*; D003114:Colony-Forming Units Assay; D004305:Dose-Response Relationship, Drug; D024901:Drug Resistance, Multiple, Bacterial; D005000:Ethionamide / Q000627:therapeutic use*; D005260:Female; D024841:Fluoroquinolones; D000077734:Gatifloxacin; D008168:Lung / Q000382:microbiology; D051379:Mice; D008810:Mice, Inbred C57BL; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D014376:Tuberculosis / Q000188:drug therapy* / Q000382:microbiology
D000890:Anti-Infective Agents; D000995:Antitubercular Agents; D024841:Fluoroquinolones; D000077734:Gatifloxacin; D005000:Ethionamide